Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 2 reviews · Neonatal

No studies found 3 · 37.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 62.5%High 0 · 0%

Methylxanthine vs placebo or control

Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine vs placebo or control

Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).

1 finding from 1 review